Compared to the more commonly used 68Ga-labeled PSMA-targeted agents, the 18F-labeled PSMA-targeted radioligand 18F-DCFPyL possesses the inherent advantages of a longer physical half-life, lower positron energy, and higher positron yield, and there have also been suggestions of a higher detection rate for sites of disease as well as an increased tumor-to-background ratio [5]. This evidence concerns the gene FOLH1 and neoplasm.